|
|
| (47 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| − | {{pnc}} | + | {{gohome}} |
| | + | {{ft|P}} |
| | + | '''CHERRYPICKING STUDIES IS NOT SCIENCE |
| | + | {{qt|Reviews on covid drug development}} |
| | | | |
| − | current items will be put into the subsections.
| |
| | | | |
| − | *[[reviews on covid drug development]] | + | *'''[[scouting ideas]]''' |
| − | *[[scouting ideas]]
| + | |
| | | | |
| − | *[[Patients on biologicals]] | + | *'''[[PHA Biologicals]]''' |
| − | *[[HMGB1, RAGE]]
| + | |
| − | *[[pre-Interleukin 6]]
| + | |
| − | *[[post-Interleukin 6]]
| + | |
| − | *[[pre-TNFalpha]]
| + | |
| − | *[[post-TNFalpha]]
| + | |
| − | *[[pre-Interleukin 17]]
| + | |
| − | *[[post-Interleukin 17]]
| + | |
| − | *[[pre-Interleukin 1]]
| + | |
| − | *[[post-Interleukin 1]]
| + | |
| − | *[[Inflammasome]] ''colchicine''
| + | |
| − | *[[other anti-inflammatory]]
| + | |
| − | *[[NK-kappaB]]
| + | |
| − | *[[STAT 3]]
| + | |
| − | *[[JAK Janus Kinase]]
| + | |
| − | *[[Corticosteroids]]
| + | |
| − | *[[Cytokine absorbers]]
| + | |
| − | *[[Target Complement system]]
| + | |
| − | *[[Target Extracellular traps]]
| + | |
| − | *[[Anticoagulant in covid19]]
| + | |
| − | *[[Antioxidants]]
| + | |
| − | *[[Stem cells]]
| + | |
| − | *[[MDSC cells]]
| + | |
| − | *[[Interferons]]
| + | |
| | | | |
| | + | *'''[[PHA conventional pharmacology]]''' |
| | | | |
| − | *[[other single compounds]] | + | *'''[[PHA retargeted compounds]]''' |
| − | *[[Retargeted single compounds]]
| + | |
| − | *[[Hydroxychloroquine]]
| + | |
| − | *
| + | |
| − | *[[Target ACE2, Spike protein]]
| + | |
| − | *[[Target TMPRSS2, Spike protein]] ''any other covid targed herein''
| + | |
| − | *[[other antiviral compounds]]
| + | |
| − | *[[AV Remdesivir]]
| + | |
| − | *[[AV Lopinavir]]
| + | |
| − | *[[AV Ivermectin]]
| + | |
| | | | |
| | + | *'''[[PHA antivirals by mechanism]]''' |
| | | | |
| | + | *'''[[PHA pharmacophore by screened target]]''' |
| | | | |
| | + | *'''[[PHA ImmunoNutrients]] |
| | | | |
| − | *[[Vitamin D]] | + | *'''[[PHA compl altern natural]]''' |
| − | *[[Anorganic nutrients Magnesium]]
| + | |
| − | *[[Anorganic nutrients Selenium]]
| + | |
| − | *[[Anorganic nutrients Zinc]]
| + | |
| − | *[[Nutrition, general]]
| + | |
| − | *[[Exercise, Vibration]]
| + | |
| | | | |
| | + | *'''[[PHA within indications compounds]]''' |
| | | | |
| − | *[[Traditional Chinese Medicine]] | + | *'''[[PHA Serum products]]''' |
| − | *[[Natural compounds]]
| + | |
| | | | |
| − | *[[Statins]] | + | *'''[[PHA Vaccination]]''' |
| − | *[[Antidiabetic compounds, any]]
| + | |
| − | *[[RSP - On RAS drugs]]
| + | |
| | | | |
| − | *[[Reconvalescent blood products, Passive vaccine]]
| + | PHA related options: |
| − | *[[Plasmapheresis]]
| + | |
| | | | |
| − | *[[Immunodeviation]] e.g. by adjuvants or other vaccinations
| |
| | *[[Radiation therapy]] | | *[[Radiation therapy]] |
| | *[[Phototherapy]] | | *[[Phototherapy]] |
| − | *[[Active vaccine]] | + | *[[Electric fields]] |
| | + | *[[Treatment other concepts]] |
| | | | |
| − | ===007===
| |
| | | | |
| − | {{tp|p=32401466|t=2006. Remdesivir|pdf=|usr=007}}
| + | A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea. |
| − | {{tp|p=32401463|t=2006. Favipiravir|pdf=|usr=007}}
| + | This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world |
| − | {{tp|p=32496248|t=2020. Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context.|pdf=|usr=007}}
| + | vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents. |
| − | {{tp|p=32496246|t=2020. Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.|pdf=|usr=007}}
| + | Paper is (not yet in PubMed) : |
| − | {{tp|p=32496241|t=2020. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32393681|t=2020. Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32468742|t=2020. Reply: Vitamin C as a Possible Therapy for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32410417|t=2020. Vitamin C as a Possible Therapy for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32476308|t=2020. Empirical Treatment and Prevention of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32466136|t=2020. Towards Precision Medicine: Inclusion of Sex and Gender Aspects in COVID-19 Clinical Studies-Acting Now before It Is Too Late-A Joint Call for Action.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32455961|t=2020. Potential Application of Whole Body Vibration Exercise For Improving The Clinical Conditions of COVID-19 Infected Individuals: A Narrative Review From the World Association of Vibration Exercise Experts (WAVex) Panel.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32486229|t=2020. Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32481690|t=2020. Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32471278|t=2020. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32471272|t=2020. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32471205|t=2020. Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32455534|t=2020. Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32443911|t=2020. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32429572|t=2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32429099|t=2020. Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32408699|t=2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32463348|t=2020. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32463308|t=2020. Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32392184|t=2020. Clinical trials for COVID-19 should include sex as a variable.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32456123|t=2020. Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32474406|t=2020. The rediscovery of hydroxychloroquine in allergic diseases in the COVID-19 era.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32457038|t=2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32451353|t=2020. Evidence of Protective Effect of Hydroxychloroquine on COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32423974|t=2020. COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32393664|t=2020. Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32475851|t=2020. COVID-19: Stay Cool toward Corticosteroids.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32475104|t=2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32293020|t=2020. Palliativ farmakologisk behandling vid svar covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32444382|t=2020. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32442946|t=2020. inverted question markBCG versus COVID-19?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32442941|t=2020. Hidroxicloroquina. Mensajes desde la cardiologia en tiempos de pandemia por coronavirus.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32490889|t=2020. Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32397399|t=2020. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32162896|t=2020. Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32407051|t=2020. Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32485894|t=2020. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32455942|t=2020. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32429580|t=2020. Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32408547|t=2020. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32486364|t=2020. Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32495926|t=2020. Does amantadine have a protective effect against COVID-19?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32397511|t=2020. 25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32486488|t=2020. Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32471251|t=2020. Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32438620|t=2020. COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492809|t=2020. Vitamin D Supplementation in Influenza and COVID-19 Infections Comment on: "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths" Nutrients 2020, 12(4), 988.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492787|t=2020. Reply: "Vitamin D Supplementation in Influenza and COVID-19 Infections. Comment on: Evidence That Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths Nutrients 2020, 12(4), 988".|pdf=|usr=007}}
| + | |
| − | {{tp|p=32418757|t=2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32471171|t=2020. Excess Ascorbate is a Chemical Stress Agent against Proteins and Cells.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32423027|t=2020. COVID-19: An Update About the Discovery Clinical Trial.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32423024|t=2020. The Rationale for Potential Pharmacotherapy of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32434254|t=2020. Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32470046|t=2020. Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32497149|t=2020. In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32505040|t=2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32491112|t=2020. Does Vitamin D play a role in the management of Covid-19 in Brazil?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32381590|t=2020. Ethics of controlled human infection to address COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32472653|t=2020. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32472939|t=2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32448818|t=2020. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32447783|t=2020. Convalescent plasma for COVID-19: Back to the future.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32449169|t=2020. How did we rapidly implement a convalescent plasma program?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32449171|t=2020. COVID-19: are neutralizing antibodies neutralizing enough?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32428966|t=2020. COVID-19 convalescent plasma donor recruitment: beware the Faustian bargains.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32395792|t=2020. COVID-19: Main therapeutic options.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32507409|t=2020. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32442105|t=2020. The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32397182|t=2020. Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32486283|t=2020. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32397643|t=2020. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32464700|t=2020. Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32485102|t=2020. Current Perspective of Antiviral Strategies against COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32369098|t=2020. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32398379|t=2020. Convalescent plasma for patients with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32398378|t=2020. Get rid of the bad first: Therapeutic plasma exchange with convalescent plasma for severe COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32398377|t=2020. Reply to Kesici et al. and Zeng et al.: Blocking the virus and reducing the inflammatory damage in COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32438839|t=2020. Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32462848|t=2020. Interleukine-1 et blocage du COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32348059|t=2020. COVID-19, dans les brouillards de l'hydroxychloroquine (4).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32320161|t=2020. Covid-19, dans les brouillards de l'hydroxychloroquine (3).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32495979|t=2020. Emergence of novel coronavirus and progress toward treatment and vaccine.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512588|t=2020. Challenges in the Production of Convalescent Hyperimmune Plasma in the Age of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32453251|t=2020. Extracorporeal Hemoadsorption: An Option for COVID-19 Associated Cytokine Storm Syndrome.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32496422|t=2020. Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32500793|t=2020. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32380908|t=2020. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32510799|t=2020. The Application Of Plasmapheresis For Covid-19 Patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32501607|t=2020. Selective C-reactive protein (CRP) apheresis for Covid-19 patients suffering from organ damage.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32433189|t=2020. Important interactions of immunosuppressants with experimental therapies for novel coronavirus disease (COVID-19): how to act.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32402475|t=2020. Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32473596|t=2020. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32491199|t=2020. Feasibility of a Pilot Program for COVID-19 Convalescent Plasma Collection in Wuhan, China.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32500936|t=2020. Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32400382|t=2020. [Brug af hydroxychloroquin til COVID-19].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32400380|t=2020. [Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32391669|t=2020. [Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32391667|t=2020. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32391659|t=2020. [Pharmaceutical care for severe and critically ill patients with COVID-19].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32458599|t=2020. [Pharmacological characteristics of chloroquine and suggestions for its use in treatment of coronavirus disease 2019 (COVID-19)].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32489024|t=2020. [Discovery of intervention effect of Chinese herbal formulas on COVID-19 pulmonary fibrosis treated by VEGFR and FGFR inhibitors].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32450629|t=2020. [Application of convalescent plasma therapy on novel coronavirus infection].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32034899|t=2020. [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32023685|t=2020. [Potential antiviral therapeutics for 2019 Novel Coronavirus].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32075365|t=2020. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32057209|t=2020. [Pharmacotherapeutics for the New Coronavirus Pneumonia].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32397700|t=2020. [Analysis of application of herd immunity as a control strategy for COVID-19].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32388937|t=2020. [Real-world efficacy and safety of lopinavir/ritonavir and arbidol in treating with COVID-19 : an observational cohort study].|pdf=|usr=007}}
| + | |
| | | | |
| − | {{tp|p=32473600|t=2020. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.|pdf=|usr=007}}
| + | *'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]''' |
| − | {{tp|p=32491981|t=2020. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.|pdf=|usr=007}}
| + | credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today. |
| − | {{tp|p=32487283|t=2020. Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.|pdf=|usr=007}}
| + | based on e.g. |
| − | {{tp|p=32490731|t=2020. Targeting SARS-CoV-2 Receptors as a Means for Reducing Infectivity and Improving Antiviral and Immune Response: An Algorithm-based Method For Overcoming Resistance To Antiviral Agents.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32432977|t=2020. Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32403995|t=2020. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32499303|t=2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32496239|t=2020. Potential pharmacological agents for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32496238|t=2020. COVID-19 vaccine development and the way forward.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32496237|t=2020. AYUSH for COVID-19: Science or Superstition?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32454489|t=2020. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32392562|t=2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32436995|t=2020. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32436994|t=2020. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32510105|t=2020. COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging beyond Topics.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32476594|t=2020. Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32462719|t=2020. Nutrition Therapy in Critically Ill Patients with Coronavirus Disease (COVID-19).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32505467|t=2020. Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32505245|t=2020. COVID-19 vaccine development pipeline gears up.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32505909|t=2020. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512490|t=2020. Potential role of zinc supplementation in prophylaxis and treatment of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492560|t=2020. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32460209|t=2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512493|t=2020. The effects of allium sativum on immunity within the scope of COVID-19 infection.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32454510|t=2020. Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492996|t=2020. Management of nutritional consultations in local clinics during SARS-CoV-2 pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492298|t=2020. Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492293|t=2020. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32487990|t=2020. Modeling mitigation of influenza epidemics by baloxavir.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32506067|t=2020. Covid-19 and Exercise-Induced Immunomodulation.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32446287|t=2020. Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32468635|t=2020. Food as medicine: a possible preventive measure against coronavirus disease (COVID-19).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32442323|t=2020. Curcumin as a potential treatment for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32430996|t=2020. Potential effects of curcumin in the treatment of COVID-19 infection.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32424845|t=2020. Artemisia annua: Trials are needed for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503877|t=2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32510169|t=2020. A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32501538|t=2020. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492211|t=2020. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492210|t=2020. Tocilizumab Administration in Patients with SARS-CoV-2 Infection: Subcutaneous Injection versus Intravenous Infusion.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492205|t=2020. COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492200|t=2020. Remdesivir and Tocilizumab: Mix or Match.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32484930|t=2020. ''Tociluzumab challenge: A series of cytokine storm therapy experience in hospitalized Covid-19 pneumonia patients''.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32484915|t=2020. Feasibility of Tocilizumab in ICU patients with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32421836|t=2020. Potential pharmacological perspectives for the treatment/prevention of the SARS-COV-2 infection in opioid dependent patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32496442|t=2020. Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32490532|t=2020. HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32506862|t=2020. Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32427774|t=2020. Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32427277|t=2020. Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32495940|t=2020. Probiotics and COVID-19: is there any link?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32504751|t=2020. A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32505910|t=2020. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1beta/neutrophil extracellular traps feedback loop.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32502901|t=2020. Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32498009|t=2020. Mass intake of hydroxychloroquine or chloroquine in the present context of the Covid-19 outbreak: Possible consequences in endemic malaria settings.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32505070|t=2020. Nebulized Lidocaine in COVID-19, An Hypothesis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32463026|t=2020. A Novel Vaccine Employing Non-Replicating Rabies Virus Expressing Chimeric SARS-CoV-2 Spike Protein Domains: Functional Inhibition of Viral/Nicotinic Acetylcholine Receptor Complexes.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32506110|t=2020. Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32459919|t=2020. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32369285|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32369284|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32369283|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32369282|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32369281|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32412709|t=2020. Compassionate Use of Remdesivir in Covid-19. Reply.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32412708|t=2020. Compassionate Use of Remdesivir in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32412707|t=2020. Compassionate Use of Remdesivir in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32412706|t=2020. Compassionate Use of Remdesivir in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32412705|t=2020. Compassionate Use of Remdesivir in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32438383|t=2020. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32325475|t=2020. The post-lockdown period should be used to acquire effective therapies for future resurgence in SARS-Cov-2 infections.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32472069|t=2020. Questions remain following first COVID-19 vaccine results.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32393915|t=2020. Biggest COVID-19 trial tests repurposed drugs first.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32417850|t=2020. Drug researchers pursue new lines of attack against COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32415300|t=2020. Biotech companies prepare for COVID-19 downturn.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32415251|t=2020. 15 drugs being tested to treat COVID-19 and how they would work.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32488217|t=2020. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32382072|t=2020. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32422645|t=2020. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32415276|t=2020. The sprint to solve coronavirus protein structures - and disarm them with drugs.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32409766|t=2020. Dozens of coronavirus drugs are in development - what happens next?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32405023|t=2020. Coronavirus drugs trials must get bigger and more collaborative.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32203367|t=2020. Coronavirus vaccines: five key questions as trials begin.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512579|t=2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32504019|t=2020. The coronavirus outbreak could make it quicker and easier to trial drugs.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32424192|t=2020. CRISPR tool scales up to interrogate a huge line-up of viral suspects.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32273621|t=2020. If a coronavirus vaccine arrives, can the world make enough?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32299148|t=2020. Considerations for Obesity, Vitamin D, and Physical Activity Amid the COVID-19 Pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32324363|t=2020. [A szerzett hosszu-QT-szindroma veszelye a koronavirus-jarvany idejen. Fokuszban a hidroxiklorokin]|pdf=|usr=007}}
| + | |
| − | {{tp|p=32324361|t=2020. [Farmakoterapias lehetosegek SARS-CoV-2-fertozes/COVID-19-betegseg eseten]|pdf=|usr=007}}
| + | |
| − | {{tp|p=32427644|t=2020. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines: Setting Expectations Appropriately.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32398330|t=2020. A Call for Pediatric COVID-19 Clinical Trials.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32423342|t=2020. COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32393419|t=2020. Recent advances of therapeutic targets and potential drugs of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32476189|t=2020. SARS-CoV-2 pandemic and Vitamin D deficiency-A double trouble.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32472655|t=2020. Cytokine storm in COVID-19 and parthenolide: preclinical evidence.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32501634|t=2020. Can Hypericum perforatum (SJW) prevent cytokine storm in COVID-19 patients?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32488956|t=2020. Can concomitant use of zinc and curcumin with other immunity-boosting nutraceuticals be the arsenal against COVID-19?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32496926|t=2020. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32439730|t=2020. Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32295814|t=2020. Hydroxychloroquine and covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32116200|t=2020. COVID-19: Perspectives on the Potential Novel Global Threat.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32472681|t=2020. Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32385052|t=2020. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32381697|t=2020. The race is on for antibodies that stop the new coronavirus.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32381692|t=2020. Combination prevention for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32393526|t=2020. A strategic approach to COVID-19 vaccine R&D.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32385100|t=2020. Rapid COVID-19 vaccine development.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32461212|t=2020. Reducing transmission of SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32385101|t=2020. Rapid repurposing of drugs for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32327575|t=2020. NIH organizes hunt for drugs.|pdf=|usr=007}}
| + | |
| | | | |
| − | {{tp|p=32409439|t=2020. Practical aspects of targeting IL-6 in COVID-19 disease.|pdf=|usr=007}} | + | {{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}} |
| − | {{tp|p=32409433|t=2020. Antivirals for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32456769|t=2020. Early tocilizumab treatment could improve survival among COVID-19 patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32456767|t=2020. Anakinra in COVID-19 therapy: what have we learned from adult-onset Still's disease?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32452345|t=2020. The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32490931|t=2020. 17beta-Estradiol, a potential ally to alleviate SARS-CoV-2 infection.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32444482|t=2020. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32409522|t=2020. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32420637|t=2020. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32294756|t=2020. Intervencoes nao farmacologicas para o enfrentamento a epidemia da COVID-19 no Brasil.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32441894|t=2020. Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32438473|t=2020. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32437587|t=2020. COVID-19 vaccines: knowing the unknown.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32460358|t=2020. The early landscape of COVID-19 vaccine development in the UK and rest of the world.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32496938|t=2020. A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512271|t=2020. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512383|t=2020. Mitigating Coronavirus-Induced Acute Respiratory Distress Syndrome by Radiotherapy.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32448039|t=2020. In-silico strategies for probing chloroquine based inhibitors against SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32448098|t=2020. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32448034|t=2020. Identification of phytochemical inhibitors against main protease of COVID-19 using molecular modeling approaches.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32448085|t=2020. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32452282|t=2020. Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32431217|t=2020. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M(pro)) of SARS-CoV-2 and inhibit its activity.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32419646|t=2020. Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32410504|t=2020. Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2-a molecular dynamic study.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32396767|t=2020. Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32469418|t=2020. Evaluation of potential therapeutic options for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32445400|t=2020. Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32441805|t=2020. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32437001|t=2020. Intuitive Global Insight Into COVID-19 Clinical Research Activities-The "COVID-19 Map of Hope".|pdf=|usr=007}}
| + | |
| − | {{tp|p=32434282|t=2020. Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32472779|t=2020. Food protein-derived antihypertensive peptides in the COVID-19 pandemic: friends of foes?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32508069|t=2020. Therapeutic Temperature Modulation for a Critically Ill Patient with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32470199|t=2020. Metformin use amid coronavirus disease 2019 pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32470160|t=2020. Glucocorticoid therapy delays the clearance of SARS-CoV-2 RNA in an asymptomatic COVID-19 patient.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32470146|t=2020. Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32462717|t=2020. COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32458502|t=2020. Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32458475|t=2020. Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32458488|t=2020. Potential negative effects of the free use of chloroquine to manage COVID-19 in Colombia.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32458425|t=2020. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32441786|t=2020. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32437024|t=2020. Convalescent plasma therapy: A passive therapy for an aggressive COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32437019|t=2020. Baricitinib: A chance to treat COVID-19?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32437014|t=2020. A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32463459|t=2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492084|t=2020. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32428941|t=2020. Potential Unconventional Medicines for the Treatment of SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32498081|t=2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32474918|t=2020. An open label cluster randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 (ARCHAIC) - Protocol publication.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32500556|t=2020. Doubtful precipitation of hemolysis by hydroxychloroquine in glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32499314|t=2020. Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32449669|t=2020. A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32432527|t=2020. Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32495917|t=2020. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32495916|t=2020. Tocilizumab in the treatment of a critical COVID-19 patient: a case report.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32495848|t=2020. Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32380868|t=2020. Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32406282|t=2020. Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32427004|t=2020. Can 3D printing of oral drugs help fight the current COVID-19 pandemic (and similar crisis in the future)?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32452701|t=2020. An up-to-date overview of computational polypharmacology in modern drug discovery.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32442040|t=2020. SARS-CoV-2, from its current highly contagious spreading toward the global development of an effective and safe vaccine: challenges and uncertainties.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32447996|t=2020. Treatments in the COVID-19 pandemic: an update on clinical trials.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32475183|t=2020. Does lopinavir measure up in the treatment of COVID-19?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32348165|t=2020. Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32282262|t=2020. Treatment considerations for coronavirus (COVID-19).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32469280|t=2020. COVID-19: Gene Transfer to the Rescue?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32423245|t=2020. The Impact of the COVID-19 Pandemic on the Biotech Industry.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32212981|t=2020. A Message to Our Community in the Midst of the COVID-19 Pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32501133|t=2020. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503817|t=2020. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503816|t=2020. Oral Methioninase for Covid-19 Methionine-restriction Therapy.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503815|t=2020. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503814|t=2020. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32449676|t=2020. COVID-19: Pentoxifylline as a potential adjuvant treatment.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32468014|t=2020. Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic insights into current COVID19 therapies (Review).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32401694|t=2020. Flying by the seat of our pants: is low dose radiation therapy for COVID-19 an option?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32474476|t=2020. Risk of using hydroxychloroquine as a treatment of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32468508|t=2020. Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32310670|t=2020. Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32473020|t=2020. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32457980|t=2020. Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32443151|t=2020. Lopinavir pharmacokinetics in COVID-19 patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32462858|t=2020. Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32469279|t=2020. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32469265|t=2020. Docking study of Chloroquine and Hydroxychloroquine interaction with SARS-CoV-2 spike glycoprotein-An in silico insight into the comparative efficacy of repurposing antiviral drugs.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32462988|t=2020. A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32406317|t=2020. Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32475223|t=2020. Antiviral effects of probiotic metabolites on COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32462970|t=2020. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32456606|t=2020. Synergistic effect of vitamin D and remdesivir can fight COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32462996|t=2020. Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32476576|t=2020. Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32476574|t=2020. Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32485061|t=2020. Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32487869|t=2020. COVID-19 and myocardial injury: is there a role for interleukin-1 inhibition?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32433345|t=2020. The pharmacological development of direct acting agents for emerging needed therapy against SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32511763|t=2020. Colchicine and COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32473011|t=2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32504739|t=2020. Interleukin-17: A potential therapeutic target in COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32473010|t=2020. TPE-nAbs combination therapy for severe COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32220033|t=2020. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32500858|t=2020. Serum concentrations of interleukin-6 (IL-6) in the general adult population: possible implications for anti-IL-6 therapy in SARS-Cov-2 infection and IL-6-related diseases.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32511912|t=2020. COVID-19: Drug targets and potential treatments.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32469301|t=2020. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32380930|t=2020. Chloroquine and the potential adverse outcome in undiagnosed G6PD-deficient cases infected with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32472703|t=2020. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32427773|t=2020. Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32364561|t=2020. Randomized Clinical Trials and COVID-19: Managing Expectations.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32463427|t=2020. Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32453363|t=2020. No Benefit for Lopinavir-Ritonavir in Severe COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492105|t=2020. A Randomized Trial of Convalescent Plasma for COVID-19-Potentially Hopeful Signals.|pdf=|usr=007}}
| + | |
| | | | |
| − | {{tp|p=32506195|t=2020. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.|pdf=|usr=007}}
| + | ======================================================================================= |
| − | {{tp|p=32438459|t=2020. Efficacy, safety and cost-effectiveness of hydroxychloroquine in children with COVID-19: A call for evidence.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32463794|t=2020. Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32432810|t=2020. Letter: does vitamin D have a potential role against COVID-19?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32434272|t=2020. COVID-19Clinical trials: quality matters more than quantity.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32384798|t=2020. Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32464736|t=2020. A simulation training course for family medicine residents in China managing COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32505821|t=2020. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32485858|t=2020. Javamide-II Inhibits IL-6 without Significant Impact on TNF-alpha and IL-1beta in Macrophage-Like Cells.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32455629|t=2020. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32441299|t=2020. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32398343|t=2020. Should azithromycin be used to treat COVID-19? A rapid review.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32464624|t=2020. Cytokine Blood Filtration Responses in COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32454500|t=2020. Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32453693|t=2020. Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".|pdf=|usr=007}}
| + | |
| − | {{tp|p=32453692|t=2020. Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32453687|t=2020. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503874|t=2020. Efficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trials.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32267762|t=2020. Research towards treating COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32453903|t=2020. Efficacy of therapeutic plasma exchange in severe COVID-19 patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32438450|t=2020. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32433778|t=2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32442317|t=2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32441783|t=2020. A rationale for targeting the P2X7 receptor in Coronavirus disease 19 (Covid-19).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32441764|t=2020. Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32424836|t=2020. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32449802|t=2020. May we target double membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512007|t=2020. Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32445484|t=2020. A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32438446|t=2020. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32508009|t=2020. Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32441462|t=2020. Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32511867|t=2020. Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin with Different Dosing Regimens used in COVID-19 Clinical Trials.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32418327|t=2020. Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32449939|t=2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32420958|t=2020. Sofosbuvir as a potential option for the treatment of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32420947|t=2020. Stop playing with data: there is no sound evidence that Bacille Calmette-Guerin may avoid SARS-CoV-2 infection (for now).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32420936|t=2020. Treatments for COVID-19: emerging drugs against the coronavirus.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32425152|t=2020. Medicines for the Treatment Of COVID-19: Awaiting the Evidence.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32506621|t=2020. Drugs being investigated for children with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32468505|t=2020. Association between low vitamin D and COVID-19: don't forget the vitamin D binding protein.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32423954|t=2020. Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32496210|t=2020. Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-alpha1b for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32493028|t=2020. Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32362105|t=2020. What information can I share with my patients about nutrition during COVID-19?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32510142|t=2020. alpha-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32407491|t=2020. iBioProVis: Interactive Visualization and Analysis of Compound Bioactivity Space.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32457999|t=2020. Tocilizumab not associated with increased infection risk after CAR T - Implications for COVID-19?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32403134|t=2020. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32430461|t=2020. Lack of efficacy of hydroxychloroquine in covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503805|t=2020. Covid-19: Hydroxychloroquine was ineffective as postexposure prophylaxis, study finds.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32487664|t=2020. Covid-19: 146 researchers raise concerns over chloroquine study that halted WHO trial.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32269046|t=2020. Chloroquine and hydroxychloroquine in covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32345591|t=2020. RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32303505|t=2020. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32407551|t=2020. Interrogation of the safety and efficacy of home-use light-based devices.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32480422|t=2020. Interleukin-6 Blockade Treatment for COVID-19 associated Cytokine Release Syndrome in a Patient with Poorly Controlled Chronic Myeloid Leukaemia.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32480418|t=2020. Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of severe COVID-19 patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32415690|t=2020. Acute chloroquine poisoning: A comprehensive experimental toxicology assessment of the role of diazepam.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32498751|t=2020. Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32498742|t=2020. SARS-CoV-2 (COVID-19) Vaccine Development and Production: An Ethical Way Forward.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32429705|t=2020. COVID-19 and Nutrition: The Need for Initiatives to Promote Healthy Eating and Prevent Obesity in Childhood.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32436730|t=2020. Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32347743|t=2020. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32412788|t=2020. beta-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32501756|t=2020. Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32267732|t=2020. Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503806|t=2020. The World of Clinical Trial Development Post-Covid-19: Lessons Learned from a Global Pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32474583|t=2020. In Reply: COVID-19: An Argument for Rapid Access to Laboratory Data Warehouses.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32459003|t=2020. A role for retinoids in the treatment of COVID-19?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32474576|t=2020. Dose Optimization of Hydroxychloroquine for COVID-19: Do Blood Concentrations Matter?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32459832|t=2020. Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32442287|t=2020. Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32435791|t=2020. Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32427279|t=2020. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32497168|t=2020. On setting expectations for a SARS-CoV-2 Vaccine.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492123|t=2020. The Importance of Advancing SARS-CoV-2 Vaccines in Children.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503801|t=2020. Does vitamin D deficiency increase the severity of COVID-19?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32341077|t=2020. Nutritional status and COVID-19: an opportunity for lasting change?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32303497|t=2020. Chloroquine and COVID-19 - a potential game changer?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32498131|t=2020. Pandemic Best Regulatory Practices: An Urgent Need in the Covid-19 Pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32488861|t=2020. Applied Clinical Pharmacology in a Crisis - Interleukin-6 Axis Blockade and COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32350861|t=2020. COVID-19: A Defining Moment for Clinical Pharmacology?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32442315|t=2020. Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32237918|t=2020. Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32475019|t=2020. Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32420691|t=2020. Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32212378|t=2020. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32406927|t=2020. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32284037|t=2020. Perspective on the COVID-19 Coronavirus Outbreak.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32174284|t=2020. A Generic Computer-Assisted Four-Pronged Approach for the Management of Emerging Global Pathogens: Some Comments on COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32400323|t=2020. In vitro data of current therapies for SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32427000|t=2020. Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32436829|t=2020. Triazavirin - Potential inhibitor for 2019-nCoV Coronavirus M protease: A DFT study.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32487877|t=2020. Editorial: Challenges and Insights amidst the Covid-19 pandemic: Nutrition, the immune system and disease risk.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32487876|t=2020. Nutrition in times of Covid-19, how to trust the deluge of scientific information.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32479246|t=2020. Mesenchymal Stem Cell-based Therapy for COVID-19: Possibility and Potential.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32416679|t=2020. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32394841|t=2020. COVID-19: An Update on Clinical Trials.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32282303|t=2020. Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32475041|t=2020. Potential role of Anti-IL-17 in COVID-19 treatment.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32473070|t=2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32510814|t=2020. Omalizumab and COVID19 Treatment: Could It Help?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32510734|t=2020. Azithromycin and COVID-19Prompt Early Use at First Signs of this Infection in Adults and Children An Approach Worthy of Consideration.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32510719|t=2020. Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32500633|t=2020. "Thinking outside the box in COVID-19 era"-Application of Modified Aerosol Box in Dermatology.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32419517|t=2020. Emerging therapies for COVID-19 pneumonia.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32429703|t=2020. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32419524|t=2020. Old and re-purposed drugs for the treatment of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32223349|t=2020. How could artificial intelligence aid in the fight against coronavirus?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32490453|t=2020. Luminescent silicon nanostructures and COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32500928|t=2020. COVID-19 breakthroughs: separating fact from fiction.|pdf=|usr=007}}
| + | |
| | | | |
| − | {{tp|p=32505474|t=2020. Battle against COVID-19: Efficacy of Convalescent Plasma as an emergency therapy.|pdf=|usr=007}}
| + | COVID19 is now a CURABLE disease !!! |
| − | {{tp|p=32419212|t=2020. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32505362|t=2020. Investigate Oral Zinc as a Prophylactic Treatment for Those at Risk for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32401673|t=2020. Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32420751|t=2020. Evaluation of the Adjuvant Efficacy of Natural Herbal Medicine on COVID-19: A Retrospective Matched Case-Control Study.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32428965|t=2020. Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease 2019 Pandemic: A Review of International Registries.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32479158|t=2020. Reply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32464083|t=2020. P-selectin blockade in COVID-19-related ARDS.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32437628|t=2020. COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32476261|t=2020. Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32458795|t=2020. Mass Drug Administration and Worms Experience in Africa: Envisage Repurposing Ivermectin for SARS-COV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32446312|t=2020. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503855|t=2020. Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503853|t=2020. COVID-19 infection in a patient with FMF: does colchicine have a protective effect?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32327429|t=2020. Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32295788|t=2020. Does hydroxychloroquine prevent the transmission of COVID-19?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32295786|t=2020. Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32345618|t=2020. Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev et al.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32340978|t=2020. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32321722|t=2020. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32317316|t=2020. Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32317315|t=2020. Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?|pdf=|usr=007}}
| + | |
| | | | |
| − | -rest-
| + | ======================================================================================= |
| − | {{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}}
| + | |
| − | {{tp|p=32276453|t=2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats |pdf=|usr=}}
| + | |
| − | {{tp|p=32325124|t=ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals |pdf=|usr=}}
| + | |
| − | {{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32336674|t=ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research |pdf=|usr=}}
| + | |
| − | {{tp|p=32356251|t=ä. Medical Toxicology and COVID-19: Our Role in a Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32243778|t=2020. Ensuring global access to COVID-19 vaccines |pdf=|usr=}}
| + | |
| − | {{tp|p=32247324|t=2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings |pdf=|usr=}}
| + | |
| − | {{tp|p=32272857|t=2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks |pdf=|usr=}}
| + | |
| − | {{tp|p=C7190525|t=2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32129977|t=2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases |pdf=|usr=}}
| + | |
| − | {{tp|p=29115746|t=2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies |pdf=|usr=}}
| + | |
| − | {{tp|p=29717819|t=2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens |pdf=|usr=}}
| + | |
| − | {{tp|p=C7194243|t=ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion |pdf=|usr=}}
| + | |
| − | {{tp|p=32383008|t=ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32380052|t=2020. Granulocyte-targeted therapies for airway diseases |pdf=|usr=}}
| + | |
| − | {{tp|p=32452420|t=2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro |pdf=|usr=}}
| + | |
